The Emerging Roles of miR-125b in Cancers

Figures & data

Table 1 The Target Genes of miR-125b in Different Cancers

Cancer Type	Expression in Tumor	Sample	Target Gene	References
Nasopharyngeal carcinoma (NPC)	Upregulation	Tissues	A20	^Citation13
	Downregulation in DDP-resistant cell	Cell lines	Bcl2	^Citation14
Retinoblastoma (RB)	Upregulation	Cell lines	DRAM2	^Citation15
Glioblastoma (GBM)	Upregulation	Tissues, cell lines	p53, P38mapk, NKIRAS2, PIAS3, FZD6	^Citation16^–^Citation19
	Upregulation in TMZ-resistant cell	Cell lines	Bak1	^Citation20
Non-small cell lung cancer (NSCLC)	Upregulation in poorly differentiated NSCLC	Cell lines	TP53INP1	^Citation21
	Downregulation in tumor	Cell lines	KLC2	^Citation27
Acute lymphoblastic leukemia (ALL)	Upregulation	Leukemic cells	A20, Bcl2	^Citation22,Citation99
Acute myeloid leukemia (AML)	Upregulation	Leukemic cells	CBFβ	^Citation23
Gastric cancer	Upregulation	Tissues	STARD13, NEU1, PPP1CA	^Citation24^–^Citation26
Esophageal squamous cell carcinoma (ESCC)	Downregulation	Tissues	HMGA2, STAT3	^Citation28,Citation29
Anaplastic thyroid cancer cell (ATC)	Downregulation	Tissues	PIK3CD	^Citation30
Bladder cancer	Downregulation	Tissues	Trop-2, SphK1, E2F3, SIRT7, MALAT1, MMP13	^Citation31^–^Citation35
Hepatocellular carcinoma (HCC)	Downregulation	Tissues	Angpt2, SMAD2, SMAD4, Mcl-1, Bcl-w, IL-6R, EIF5A2	^Citation36^–^Citation39
Melanoma	Downregulation	Tissues	ITGA9, NEDD9, c-jun	^Citation40,Citation41
Ovarian Cancer	Downregulation	Tissues	SET, EIF4EBP1, BCL3	^Citation42^–^Citation44
Osteosarcoma	Downregulation	Tissues	Bcl2, STAT3, HK2	^Citation45^–^Citation47
Chondrosarcoma	Downregulation	Tissues	ErbB2	^Citation48
Breast cancer	Downregulation	Tissues	TSTA3, MAP2K7, STARD13, ETS1, ENPEP, CK2-α, CCNJ, MEGF9, EPO, EPOR, MUC1	^Citation49^–^Citation55
Gallbladder cancer (GBC)	Downregulation	Tissues	Bcl2	^Citation56
Endometrioid endometrial cancer (EEC)	Downregulation	Tissues	ErbB2	^Citation57
Colorectal cancer (CRC)	Downregulation	Tissues	NA	^Citation58,Citation59
	Upregulation in cexutimab-resistant CRC	Tissues	DKK3, ZNRF3, RNF43, APC2	^Citation11
Cervical cancer (CC)	Upregulation	Cell lines	HMGA1	^Citation100
Multiple myeloma (MM)	Downregulation	Cell lines	MALAT1, STAT3	^Citation60,Citation101
Ewing’s sarcoma (ES)	Downregulation	Tissues	PIK3CD	^Citation61

Figure 1 The role of miR-125b in the development of cancer.

Zheng Z, Qu JQ, Yi HM, et al. MiR-125b regulates proliferation and apoptosis of nasopharyngeal carcinoma by targeting A20/NF-kappaB signaling pathway. Cell Death Dis. 2017;8(6):e2855. doi:10.1038/cddis.2017.21128569771

 PubMedGoogle Scholar

Yuan TZ, Zhang HH, Lin XL, et al. microRNA-125b reverses the multidrug resistance of nasopharyngeal carcinoma cells via targeting of Bcl-2. Mol Med Rep. 2017;15(4):2223–2228. doi:10.3892/mmr.2017.623328260044

 PubMed Web of Science ®Google Scholar

Bai S, Tian B, Li A, Yao Q, Zhang G, Li F. MicroRNA-125b promotes tumor growth and suppresses apoptosis by targeting DRAM2 in retinoblastoma. Eye (Lond). 2016;30(12):1630–1638. doi:10.1038/eye.2016.18927518550

 PubMed Web of Science ®Google Scholar

Wu N, Lin X, Zhao X, et al. MiR-125b acts as an oncogene in glioblastoma cells and inhibits cell apoptosis through p53 and p38MAPK-independent pathways. Br J Cancer. 2013;109(11):2853–2863. doi:10.1038/bjc.2013.67224169356

 PubMed Web of Science ®Google Scholar

Huang T, Alvarez AA, Pangeni RP, et al. A regulatory circuit of miR-125b/miR-20b and Wnt signalling controls glioblastoma phenotypes through FZD6-modulated pathways. Nat Commun. 2016;7:12885. doi:10.1038/ncomms1288527698350

 PubMed Web of Science ®Google Scholar

Chen J, Fu X, Wan Y, Wang Z, Jiang D, Shi L. miR-125b inhibitor enhance the chemosensitivity of glioblastoma stem cells to temozolomide by targeting Bak1. Tumour Biol. 2014;35(7):6293–6302. doi:10.1007/s13277-014-1821-424643683

 PubMed Web of Science ®Google Scholar

Li Q, Han Y, Wang C, et al. MicroRNA-125b promotes tumor metastasis through targeting tumor protein 53-induced nuclear protein 1 in patients with non-small-cell lung cancer. Cancer Cell Int. 2015;15:84. doi:10.1186/s12935-015-0233-x26388699

 PubMed Web of Science ®Google Scholar

Wang M, Zhu X, Sha Z, Li N, Li D, Chen L. High expression of kinesin light chain-2, a novel target of miR-125b, is associated with poor clinical outcome of elderly non-small-cell lung cancer patients. Br J Cancer. 2015;112(5):874–882. doi:10.1038/bjc.2015.325668010

 PubMed Web of Science ®Google Scholar

Liu Z, Smith KR, Khong HT, et al. miR-125b regulates differentiation and metabolic reprogramming of T cell acute lymphoblastic leukemia by directly targeting A20. Oncotarget. 2016;7(48):78667–78679. doi:10.18632/oncotarget.1201827637078

 PubMedGoogle Scholar

El-Khazragy N, Elshimy AA, Hassan SS, et al. Dysregulation of miR-125b predicts poor response to therapy in pediatric acute lymphoblastic leukemia. J Cell Biochem. 2018.

 Web of Science ®Google Scholar

Lin K-Y, Zhang X-J, Feng -D-D, et al. miR-125b, a target of CDX2, regulates cell differentiation through repression of the core binding factor in hematopoietic malignancies. J Biol Chem. 2011;286(44):38253–38263. doi:10.1074/jbc.M111.26967021903586

 PubMed Web of Science ®Google Scholar

Sui M, Jiao A, Zhai H, et al. Upregulation of miR-125b is associated with poor prognosis and trastuzumab resistance in HER2-positive gastric cancer. Exp Ther Med. 2017;14(1):657–663. doi:10.3892/etm.2017.454828672982

 PubMed Web of Science ®Google Scholar

Wu J-G, Wang -J-J, Jiang X, et al. MiR-125b promotes cell migration and invasion by targeting PPP1CA-Rb signal pathways in gastric cancer, resulting in a poor prognosis. Gastric Cancer. 2015;18(4):729–739. doi:10.1007/s10120-014-0421-825240408

 PubMed Web of Science ®Google Scholar

Mei LL, Wang W-J, Qiu Y-T, Xie X-F, Bai J, Shi Z-Z. miR-125b-5p functions as a tumor suppressor gene partially by regulating HMGA2 in esophageal squamous cell carcinoma. PLoS One. 2017;12(10):e0185636. doi:10.1371/journal.pone.018563628968424

 PubMed Web of Science ®Google Scholar

Feng J, Fan Y, Ayiheng Q, Zhang H, Yong J, Hu B. MicroRNA-125b targeted STAT3 to inhibit laryngeal squamous cell carcinoma cell growth and motility. Oncol Lett. 2017;14(1):480–486. doi:10.3892/ol.2017.615528693195

 PubMed Web of Science ®Google Scholar

Bu Q, You F, Pan G, et al. MiR-125b inhibits anaplastic thyroid cancer cell migration and invasion by targeting PIK3CD. Biomed Pharmacother. 2017;88:443–448. doi:10.1016/j.biopha.2016.11.09028122310

 PubMed Web of Science ®Google Scholar

Avellini C, Licini C, Lazzarini R, et al. The trophoblast cell surface antigen 2 and miR-125b axis in urothelial bladder cancer. Oncotarget. 2017;8(35):58642–58653. doi:10.18632/oncotarget.v8i3528938585

 PubMedGoogle Scholar

Wu D, Ding J, Wang L, et al. microRNA-125b inhibits cell migration and invasion by targeting matrix metallopeptidase 13 in bladder cancer. Oncol Lett. 2013;5(3):829–834. doi:10.3892/ol.2013.112323425975

 PubMed Web of Science ®Google Scholar

Zhou HC, Fang JH, Shang LR, et al. MicroRNAs miR-125b and miR-100 suppress metastasis of hepatocellular carcinoma by disrupting the formation of vessels that encapsulate tumour clusters. J Pathol. 2016;240(4):450–460. doi:10.1002/path.480427577856

 PubMed Web of Science ®Google Scholar

Tsang FH, Au V, Lu WJ, et al. Prognostic marker microRNA-125b inhibits tumorigenic properties of hepatocellular carcinoma cells via suppressing tumorigenic molecule eIF5A2. Dig Dis Sci. 2014;59(10):2477–2487. doi:10.1007/s10620-014-3184-524811246

 PubMed Web of Science ®Google Scholar

Zhang J, Na S, Liu C, Pan S, Cai J, Qiu J. MicroRNA-125b suppresses the epithelial-mesenchymal transition and cell invasion by targeting ITGA9 in melanoma. Tumour Biol. 2016;37(5):5941–5949. doi:10.1007/s13277-015-4409-826596831

 PubMedGoogle Scholar

Kappelmann M, Kuphal S, Meister G, Vardimon L, Bosserhoff AK. MicroRNA miR-125b controls melanoma progression by direct regulation of c-jun protein expression. Oncogene. 2013;32(24):2984–2991. doi:10.1038/onc.2012.30722797068

 PubMed Web of Science ®Google Scholar

Ying X, Wei K, Lin Z, et al. MicroRNA-125b suppresses ovarian cancer progression via suppression of the epithelial-mesenchymal transition pathway by targeting the SET protein. Cell Physiol Biochem. 2016;39(2):501–510. doi:10.1159/00044564227383536

 PubMed Web of Science ®Google Scholar

Guan Y, Yao H, Zheng Z, Qiu G, Sun K. MiR-125b targets BCL3 and suppresses ovarian cancer proliferation. Int J Cancer. 2011;128(10):2274–2283. doi:10.1002/ijc.2557520658525

 PubMed Web of Science ®Google Scholar

Wang F, Yu D, Liu Z, et al. MiR-125b functions as a tumor suppressor and enhances chemosensitivity to cisplatin in osteosarcoma. Technol Cancer Res Treat. 2016;15(6):NP105–NP112. doi:10.1177/153303461561884926744308

 PubMed Web of Science ®Google Scholar

Wu Y, He H, Wu B, et al. miR-125b suppresses the aerobic glycolysis of osteosarcoma HOS cells by downregulating the expression of hexokinase-2. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2017;33(10):1365–1370.29169422

 PubMedGoogle Scholar

Tang XY, Zheng W, Ding M, et al. miR-125b acts as a tumor suppressor in chondrosarcoma cells by the sensitization to doxorubicin through direct targeting the ErbB2-regulated glucose metabolism. Drug Des Devel Ther. 2016;10:571–583. doi:10.2147/DDDT.S90530

 PubMedGoogle Scholar

Sun Y, Liu X, Zhang Q, et al. Oncogenic potential of TSTA3 in breast cancer and its regulation by the tumor suppressors miR-125a-5p and miR-125b. Tumour Biol. 2016;37(4):4963–4972. doi:10.1007/s13277-015-4178-426531722

 PubMedGoogle Scholar

Rajabi H, Jin C, Ahmad R, McClary C, Joshi MD, Kufe D. Mucin 1 oncoprotein expression is suppressed by the miR-125b oncomir. Genes Cancer. 2010;1(1):62–68. doi:10.1177/194760190935793320729973

 PubMedGoogle Scholar

Yang D, Zhan M, Chen T, et al. miR-125b-5p enhances chemotherapy sensitivity to cisplatin by down-regulating Bcl2 in gallbladder cancer. Sci Rep. 2017;7:43109. doi:10.1038/srep4310928256505

 PubMed Web of Science ®Google Scholar

Shang C, Lu YM, Meng LR. MicroRNA-125b down-regulation mediates endometrial cancer invasion by targeting ERBB2. Medi Sci Monitor. 2012;18(4):Br149–155. doi:10.12659/MSM.882617

 PubMed Web of Science ®Google Scholar

Fujino Y, Takeishi S, Nishida K, et al. Downregulation of microRNA-100/microRNA-125b is associated with lymph node metastasis in early colorectal cancer with submucosal invasion. Cancer Sci. 2017;108(3):390–397. doi:10.1111/cas.1315228032929

 PubMed Web of Science ®Google Scholar

Zhang X, Ma X, An H, et al. Upregulation of microRNA-125b by G-CSF promotes metastasis in colorectal cancer. Oncotarget. 2017;8(31):50642–50654. doi:10.18632/oncotarget.1689228881590

 PubMedGoogle Scholar

Lu Y, Zhao X, Liu Q, et al. lncRNA MIR100HG-derived miR-100 and miR-125b mediate cetuximab resistance via Wnt/beta-catenin signaling. Nat Med. 2017;23(11):1331–1341. doi:10.1038/nm.442429035371

 PubMed Web of Science ®Google Scholar

Sun B, Zhang Y, Zhou L, et al. The proliferation of cervical cancer is promoted by miRNA-125b through the regulation of the HMGA1. Onco Targets Ther. 2019;12:2767–2776. doi:10.2147/OTT.S19774031043793

 PubMed Web of Science ®Google Scholar

Gao D, Xiao Z, Li HP, Han DH, Zhang YP. The mechanism study of miR-125b in occurrence and progression of multiple myeloma. Cancer Med. 2018;7(1):134–145. doi:10.1002/cam4.118129214735

 PubMed Web of Science ®Google Scholar

Misso G, Zarone MR, Lombardi A, et al. miR-125b upregulates miR-34a and sequentially activates stress adaption and cell death mechanisms in multiple myeloma. Mol Ther Nucl Acids. 2019;16:391–406. doi:10.1016/j.omtn.2019.02.023

 Google Scholar

Li J, You T, Jing J. MiR-125b inhibits cell biological progression of Ewing’s sarcoma by suppressing the PI3K/Akt signalling pathway. Cell Prolif. 2014;47(2):152–160. doi:10.1111/cpr.2014.47.issue-224517182

 PubMed Web of Science ®Google Scholar